The next wave of therapies is almost here, and it’s a big one.
In medicine, change doesn’t slow down, it compounds. Every year, new therapies push us to rethink how we treat disease, how we counsel patients, and how healthcare actually gets delivered. As we head toward 2026, several late-stage drug launches are generating serious attention, not just because they’re new, but because they could meaningfully shift standards of care.
With 2025 coming to a close, this is the moment to look ahead: what’s coming, why it matters, and how clinicians and healthcare leaders can prepare.
Five Drugs Everyone’s Watching
Oveporexton: Treating Narcolepsy at Its Source
For years, narcolepsy care has relied on stimulants and wake-promoting agents that manage symptoms but don’t address the underlying biology. Oveporexton changes that conversation.
As a first-in-class orexin-2 receptor agonist, oveporexton directly targets the orexin system, the very pathway disrupted in narcolepsy. By mimicking the function of lost orexin neurons, it aims to restore more natural sleep–wake regulation rather than simply masking fatigue. If approved, this could represent a true shift toward disease-modifying therapy, with the potential for better wakefulness control, reduced cataplexy, and fewer trade-offs.
Bemarituzumab: Precision Oncology Comes to Gastric Cancer
Advanced gastric and gastroesophageal cancers remain difficult to treat, with limited targeted options. Bemarituzumab stands out because it zeroes in on a specific biomarker: FGFR2b overexpression.
Found in roughly 8–10% of these cancers, FGFR2b has emerged as a meaningful therapeutic target. Bemarituzumab’s biomarker-driven approach offers the promise of improved efficacy and less toxicity compared with traditional chemotherapy alone. Results from the Phase 2 FIGHT trial suggest this agent could redefine treatment for a molecularly selected patient population, and further cement precision oncology as the norm, not the exception.
CagriSema: Redefining What Obesity Treatment Can Achieve
Novo Nordisk’s CagriSema reflects how far obesity pharmacotherapy has evolved. This fixed-dose combination pairs a GLP-1 receptor agonist with cagrilintide, an amylin analog, to attack appetite and metabolic dysfunction from two complementary angles.
The goal isn’t just weight loss; it’s durability, metabolic improvement, and meaningful risk reduction for conditions like type 2 diabetes and cardiovascular disease. Early data suggest this dual-mechanism approach may outperform GLP-1 monotherapy, potentially raising expectations for what “effective” obesity treatment really means.
mRNA-1083: One Shot, Broader Protection
mRNA technology transformed vaccinology during the COVID-19 pandemic, and Moderna’s mRNA-1083 builds on that momentum. This investigational single-shot vaccine is designed to protect against both COVID-19 and seasonal influenza.
Beyond immunology, the real impact may be practical: fewer injections, less vaccine fatigue, and higher uptake. By simplifying respiratory vaccination while maintaining strong immune responses to multiple strains, mRNA-1083 points toward a future of more efficient, patient-friendly immunization strategies.
Orca-T: Rebalancing Risk in Stem Cell Transplantation
Allogeneic stem cell transplantation can be curative, but graft-versus-host disease (GVHD) remains a major barrier. Orca-T is designed to change that risk equation.
By precisely engineering the donor graft’s T-cell composition, Orca-T aims to preserve the graft-versus-leukemia effect while dramatically reducing GVHD. If outcomes hold, this therapy could make transplantation safer, more tolerable, and accessible to a broader group of patients with hematologic malignancies.
What These Launches Tell Us About Where Healthcare Is Going
Taken together, these therapies highlight clear trends:
- Precision medicine is no longer optional, it’s foundational.
- Chronic disease management, especially obesity, is being redefined.
- Vaccine development is moving toward consolidation and convenience.
- Cell therapies are expanding beyond rare or experimental use cases.
The Bigger Question
The 2026 pipeline is exciting, but excitement alone isn’t enough. We need to be ready to implement these therapies thoughtfully and create the education, infrastructure, and access pathways to ensure patients actually benefit. This is the moment not just to adapt, but to lead.
Which of these therapies are you most excited about? And what barriers do you think we’ll need to overcome to make their impact real?
Let’s keep the conversation going.
Amgen. (2022). FIGHT trial results: Bemarituzumab in FGFR2b-positive gastric cancer. https://www.amgen.com
Moderna. (2023). Moderna announces clinical progress for mRNA-1083 combination influenza and COVID-19 vaccine. https://investors.modernatx.com
Novo Nordisk. (2023). CagriSema clinical development update. https://www.novonordisk.com
Orca Bio. (2023). Orca-T: Precision-engineered allogeneic cell therapy for hematologic malignancies. https://orcabio.com
Scammell, T. E., & Winrow, C. J. (2011). Orexin receptors: Pharmacology and therapeutic opportunities. Annual Review of Pharmacology and Toxicology, 51, 243–266. https://doi.org/10.1146/annurev-pharmtox-010510-100528
